Followers | 63 |
Posts | 786 |
Boards Moderated | 0 |
Alias Born | 04/08/2022 |
Thursday, March 28, 2024 9:32:00 AM
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
March 28 2024 - 08:30AM
Share On Facebook
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer.
Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renowned institutions Yale University, University of Pittsburgh, and Harvard University. Dr. Vlock has successfully supported start-up, emerging, and established companies with diverse product portfolios. He has played key roles in managing pre-IND, phase I, II and III clinical trials, and post–approval studies for more than 40 oncology development programs. While at Pharmacia, Dr. Vlock ran the Celebrex Oncology program involving two pivotal clinical trials and over 3,500 patients. His team was responsible for European approval of Celebrex for the treatment of familial adenomatous polyposis. As CEO of Alopexx, Inc., Dr. Vlock was responsible for the development of drugs in oncology, infectious diseases, Alzheimer’s Disease and muscular dystrophy. His expertise spans important aspects of oncology development, including clinical trial design and strategy, interactions with regulatory agencies, and medical oversight of clinical trials.
“We are delighted to welcome Dr. Vlock in his new role as a senior member of the TransCode team,” said Tom Fitzgerald, CFO and Interim CEO of TransCode. “As a consultant, Dr. Vlock has provided his deep insights into our TTX-MC138 clinical development plan, including our planned Phase 1 clinical trial, and regulatory compliance. Dr. Vlock’s medical and clinical leadership will be invaluable in translating our groundbreaking science to build a robust clinical development program with TTX-MC138, our lead candidate, and our additional pipeline candidates.”
Dr. Vlock obtained his M.D. from Baylor College of Medicine. He completed his residency training in Internal Medicine at Temple University Hospital and a fellowship in Medical Oncology at Yale University School of Medicine. Dr. Vlock initially will serve on a part-time basis through TransCode’s arrangement with BioBridges LLC, a life sciences consulting company.
Recent RNAZ News
- TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 04/15/2024 01:00:00 PM
- TransCode Therapeutics Reports 2023 Results; Provides Business Update • GlobeNewswire Inc. • 04/03/2024 01:10:00 PM
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment • GlobeNewswire Inc. • 03/11/2024 01:00:00 PM
- TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress • GlobeNewswire Inc. • 03/06/2024 09:15:00 PM
- TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:00:30 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:33:08 PM
- Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market • GlobeNewswire Inc. • 01/31/2024 09:05:00 PM
- TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer • GlobeNewswire Inc. • 01/29/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 09:45:50 PM
- TransCode Therapeutics Announces Closing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/22/2024 09:45:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/20/2024 02:57:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:08 AM
- TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 06:27:45 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/18/2024 03:39:59 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/17/2024 12:06:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:22 PM
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/11/2024 01:22:19 PM
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:01:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/04/2024 05:41:41 PM
- TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives • GlobeNewswire Inc. • 01/04/2024 01:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM